In recent years in-vivo assessment of vertebral bone marrow (VBM) fat composition has been increasingly used in the investigation of osteoporosis and bone metabolism. Postmenopausal women represent a population of particular interest because they are at higher risk for osteoporosis resulting from estrogen deficiency which can be potentially aggravated by aromatase inhibitor (AI) therapy. The present study demonstrated a relative increase in vertebral bone marrow fat content quantified by chemical shift encoding-based water-fat MRI in patients receiving simultaneous AI and bisphosphonate (BP) therapy, contradicting previous findings reported in the literature.
This abstract and the presentation materials are available to members only; a login is required.